Definium Therapeutics nears pivotal MDD test as DT120 ODT faces Phase 3 scrutiny
Find out how Definium Therapeutics’ DT120 ODT Phase 3 MDD readout could reshape psychedelic psychiatry and depression drug development.
Pharma & Biotech
Medical Devices & Diagnostics
Diamond Lake Clinic’s EXOMIND rollout signals shifting priorities in noninvasive depression treatment
Diamond Lake Clinic introduces EXOMIND for depression care. Find out what this shift means for neuromodulation, evidence standards, and mental health treatment models.
Pharma & Biotech
Can ketamine treatment clinics like Serenity redefine psychiatric care delivery in suburban America?
Serenity expands ketamine therapy in Florida. Find out how this signals a shift in psychiatric care access and what clinicians are watching next.
Pharma & Biotech
Elunetirom shows synaptogenic promise as Autobahn eyes pivotal trials in depression
Autobahn’s elunetirom may offer a novel neuroplasticity-driven treatment for depression. Find out what its latest data mean for the future of MDD therapy.